Pralay Mukhopadhyay
Vice President, Medicine Development Leader GSK
Dr. Pralay Mukhopadhyay has a proven track record in oncology drug development. He currently works as Vice President, Medicine Development Leader at GlaxoSmithKline. Over the years, he has made significant contributions in the development of several anti-cancer agents in both hematologic malignancies and solid tumors. He has worked closely with health authorities across the global in addressing broader drug development challenges. He has been an invited speaker in scientific conferences and has over 60 peer reviewed publications. He currently serves in the editorial board of Frontiers in Medicine. He received his PhD in statistics from North Carolina State University.
Seminars
Tuesday 4th November 2025
Showcasing Updated Clinical Profile & Sustained Overall Survival Benefit of Belantamab Mafodotin Combination to Understand How ADC MoA Translates to Advancing to Earlier Line Oncology Treatments
9:30 am
- Breaking down the updated clinical profile of belantamab mafodotin combinations from DREAMM-7 trial with sustained overall survival benefit in patients with relapsed or refractory multiple myeloma
- Explaining how multi-modal mechanism of action across payload, immunogenic cell death, and adaptive immune response translates to durable patient response and long-term clinical benefit
- Contextualizing belantamab mafodotin’s ongoing regulatory journey
- Evaluating the journey of ADCs transitioning to earlier-line treatments for oncology patients across tumor types
